...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2018

Toinv - Zenith gets up to date information each week on the patients in each leg of the trial according to a side conversation at the AGM in Dec. 

BDAZ - Fortunately or unfortunately they are a private company and can hold onto any information for as long as they see fit. They can also disclose that information to any party they choose, under ca agreement for marketing or any other purpose. Same goes for potential investors.

Not having to disclose any scientific results could be beneficial in their sale strategy, or not.

tada

Share
New Message
Please login to post a reply